Showing 431-440 of 5061 results for "".
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- NeoStrata Launches Exuviance Triple Microdermabrasionhttps://practicaldermatology.com/news/20140530-neostrata_launches_exuviance_triple_microdermabrasion/2459226/NeoStrata Company's new Exuviance Triple Microdermabrasion, described as a three-part approach to skin renewal in one single treatment, will be available nationwide in August. Exuviance Triple Microdermabrasion is formulated with professional grade crystals and Papaya Enzymes along with 1
- Two States Pass Laws Banning Indoor Tanning for Minorshttps://practicaldermatology.com/news/20140527-two_states_pass_laws_banning_indoor_tanning_for_minors/2459230/Minnesota and Louisiana have both recently passed legislation banning the use of indoor tanning facilities for those under 18 years of age. Both laws go into effect on August 1, 2014. Nine states in total have instituted bans on indoor tanning for minors, including Vermont, California, Illinois, Ore
- Modernizing Medicine's EMA Achieves ONC HIT 2014 Edition EHR Certificationhttps://practicaldermatology.com/news/20140506-modernizing_medicines_ema_achieves_onc_hit_2014_edition_ehr_certification/2459245/Modernizing Medicine's EMA has achieved ONC HIT 2014 Edition Complete EHR certification, meaning that it will be capable of supporting eligible providers and hospitals with meeting the Stage 1 and Stage 2 Meaningful Use measures of the EHR incentive program. EMA version 4.0 and EMA Mobile version 4.
- Phase 3 Results Promising for Oral Psoriasis Agenthttps://practicaldermatology.com/news/20140422-phase_3_results_promising_for_oral_psoriasis_agent/2459260/Results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program indicate that the investigational oral Janus kinase (JAK) inhibitor tofacitinib (Pfizer) is both safe and effective for patients with moderate to severe psoriasis. The OPT Pivotal #1 and OPT Pivotal #2 stu
- XOMA Gains Orphan Drug Designation to Treat Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140225-xoma_gains_orphan_drug_designation_to_treat_pyoderma_gangrenosum/2459332/The FDA approved XOMA Corporation's IL-1 beta antibody gevokizumab for the treatment of pyoderma gangrenosum (PG) under an orphan drug designation. PG is a rare disorder of expanding, painful skin ulcers, which affects one in about 100,000 people. "Selecting pyoderma gangrenosum as our n
- Valeant's Antifungal Agent Luzu Wins FDA Approvalhttps://practicaldermatology.com/news/20131115-valeants_antifungal_luzu_wins_fda_approval/2459414/The FDA has approved Luzu® (luliconazole, Valeant) Cream, 1% for the topical treatment of athlete's foot (interdigital tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and olde
- Anti-bacterial Soap Under FDA Reviewhttps://practicaldermatology.com/news/20130520-anti-bacterial_soap_under_fda_review/2459537/The Food and Drug Administration (FDA) is studying whether triclosan is safe and effective. The FDA's findings could have implications for a $1 billion industry that includes hundreds of anti-bacterial soaps and body washes, particularly in acne washes. The review comes amid recent studies that have
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Envy Medical Unveils New Acne Systemhttps://practicaldermatology.com/news/20130311-envy_medical_unveils_new_acne_system/2459595/Envy Medical Inc. recently launched the ClarityMD Acne Solution at the American Academy of Dermatology Annual Meeting on March 1 in Miami. The system includes a Deep Pore Cleanser and Clarifying Gel in a two-step system that's clinically proven to significantly heal acne within days, according to th